References
Kim Y, et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol. 2012 Nov;86(21):11754-62.
Mohseni N, Royster A, Ren S, et al.A novel compound targets the feline infectious peritonitis virus nucleocapsid protein and inhibits viral replication in cell culture.Journal of Biological Chemistry.2023: 102976.
Theerawatanasirikul S, Kuo C J, Phecharat N, et al. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses[J]. Antiviral research,. 2020, 182: 104927.
Theerawatanasirikul S, Kuo C J, Phecharat N, et al. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses. Antiviral research, 2020, 182: 104927.
Pedersen NC, et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg. 2018 Apr;20(4):378-392.
Wang Y C, Yang W H, Yang C S, et al. Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug[J]. American Journal of Cancer Research. 2020, 10(8): 2535.
Bai Y, Ye F, Feng Y, et al. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Signal Transduction and Targeted Therapy. 2021, 6(1): 1-3
Ye X, Li Y, Guo L, et al.Synthesis and enzymatic inhibition effects of thiazolidinedione 3C-like protease inhibitors.Journal of Chemical Research.2023, 47(1): 17475198231152556.
Hahn F, Wangen C, H?ge S, et al.The Trimeric Artesunate Analog TF27, a Broadly Acting Anti-Infective Model Drug, Exerts Pronounced Anti-SARS-CoV-2 Activity Spanning Variants and Host Cell Types.Pharmaceutics.2022, 15(1): 115.
Fu L, Ye F, Feng Y, et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nature communications. 2020, 11(1): 1-8.
Herrmann A, Jungnickl D, Cordsmeier A, et al. Cloning of a Passage-Free SARS-CoV-2 Genome and Mutagenesis Using Red Recombination. International Journal of Molecular Sciences. 2021, 22(19): 10188.
Fu L, Ye F, Feng Y, et al Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nature communications. 2020 Sep 4;11(1):4417. doi: 10.1038/s41467-020-18233-x.
Chen Y, Li X, Wang M, et al.A cysteine protease inhibitor GC376 displays potent antiviral activity against coxsackievirus infection.Current Research in Microbial Sciences.2023: 100203.
Wang Y C, Yang W H, Yang C S, et al. Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug. American Journal of Cancer Research. 2020, 10(8): 2535